e-learning
resources
Vienna 2003
Monday 29.09.2003
Epidemiological aspects of COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The main disease-related cost drivers in COPD: impaired lung function and exacerbations
S. A. Jansson, A. Ericsson, A. Lindberg, S. Borg, A. C. Jonsson, E. Rönmark, F. Andersson, B. Lundbäck (Luleå, Umeå, Lund, Stockholm, Sweden)
Source:
Annual Congress 2003 - Epidemiological aspects of COPD
Session:
Epidemiological aspects of COPD
Session type:
Poster Discussion
Number:
1463
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. A. Jansson, A. Ericsson, A. Lindberg, S. Borg, A. C. Jonsson, E. Rönmark, F. Andersson, B. Lundbäck (Luleå, Umeå, Lund, Stockholm, Sweden). The main disease-related cost drivers in COPD: impaired lung function and exacerbations. Eur Respir J 2003; 22: Suppl. 45, 1463
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Irisin is associated with severe exacerbations of COPD independently of lung function, comorbidities and exercise capacity
Source: International Congress 2015 – Notable abstracts in COPD: variety
Year: 2015
Predictors of lung function deterioration in COPD
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016
Lung function impairment, COPD hospitalisations and subsequent mortality
Source: Annual Congress 2009 - Exacerbations and characteristics of COPD
Year: 2009
COPD in the time of COVID-19: an analysis of acute exacerbations and reported behavioural changes in patients with COPD
Source: ERJ Open Res, 7 (1) 00718-2020; 10.1183/23120541.00718-2020
Year: 2021
Impact of age-related comorbidities on the risk of COPD exacerbations in subjects with severe airflow limitation: A pan-European study
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
The predictors for COPD exacerbations using remote patient monitoring
Source: International Congress 2015 – Clinical assessment in asthma and COPD
Year: 2015
FEV1 decline in patients with chronic obstructive pulmonary disease: Which treatment option is better for slowing of decline?
Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction
Year: 2015
Static hyperinflation and respiratory disability were associated with frequent-exacerbation phenotype in patients with severe COPD
Source: International Congress 2016 – Exploring mechanisms in health and disease
Year: 2016
The relationship of exacerbations and lung function decline to radiologic characteristics in COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 512s
Year: 2005
COPD exacerbation: Influence of severity and type of systemic inflammation on the hospitalizations rate
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015
Difficulty in management of COPD exacerbation: Is this chronic exacerbation or difficult COPD: “A specific phenotype?”
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013
The impact of comorbidities on the short-term serious health outcomes in hospitalized COPD patients due to exacerbation
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013
Agreement of severity stages and exacerbations building the new COPD risk groups
Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation
Year: 2013
A global survey conducted to determine frequency of exacerbations in COPD patients
Source: Annual Congress 2013 –COPD treatment
Year: 2013
COPD exacerbations: impact and prevention
Source: Breathe 2013; 9: 434-440
Year: 2013
Alternative ways of expressing FEV1 and mortality in elderly people with and without COPD
Source: Eur Respir J 2013; 41: 800-805
Year: 2013
COPD: Influence of patients’ nutritive status on the exacerbations rate
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016
QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Severe exacerbations predict excess lung function decline in asthma
Source: Eur Respir J 2007; 30: 452-456
Year: 2007
Sit-to-stand ability in patients hospitalised for acute exacerbation of COPD: Clinical characteristics and short-term outcomes
Source: International Congress 2015 – New insights into exercise and muscle performance
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept